Filing Details
- Accession Number:
- 0001193125-19-167238
- Form Type:
- 13G Filing
- Publication Date:
- 2019-06-06 16:32:56
- Filed By:
- Soon-shiong Patrick
- Company:
- Ladrx Corp (NASDAQ:LADX)
- Filing Date:
- 2019-06-06
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Patrick Soon-Shiong | 1,969,697 | 1,969,697 | 1,969,697 | 5.9% | ||
ImmunityBio, Inc | 1,969,697 | 1,969,697 | 1,969,697 | 5.9% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
CytRx Corporation
(Name of Issuer)
Common Stock, Par value $0.001 per share
(Title of Class of Securities)
232828608
(CUSIP Number)
Patrick Soon-Shiong, M.D.
ImmunityBio, Inc
9922 Jefferson Boulevard
Culver City, California 90232
(310) 883-1300
With a copy to:
Martin J. Waters
Daniel R. Koeppen
Wilson Sonsini Goodrich & Rosati
Professional Corporation
12235 El Camino Real
San Diego, California 92130
(858) 350-2300
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 6, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 232828608 |
1. | Names of Reporting Persons
Patrick Soon-Shiong | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
United States |
Number of Shares Beneficially Owned by Each Reporting Person With: | 5. | Sole Voting Power
1,969,697 (See Item 4(a) below) | ||||
6. | Shared Voting Power
None | |||||
7. | Sole Dispositive Power
1,969,697 (See Item 4(a) below) | |||||
8. | Shared Dispositive Power
None |
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,969,697 (See Item 4(a) below) | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
5.9% (See Item 4(b) below) | |||||
12. | Type of Reporting Person (See Instructions)
IN |
(1) | This number represents the percentage obtained by: dividing (a) the total number of shares of the Issuers common stock being reported in this Statement 1,969,697) by (b) the number of shares of the Issuers common stock outstanding on May 14, 2019 (33,637,501), based on information publicly disclosed by the Issuer. |
CUSIP No. 232828608 |
1. | Names of Reporting Persons
ImmunityBio, Inc. | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With: | 5. | Sole Voting Power
1,969,697 (See Item 4(a) below) | ||||
6. | Shared Voting Power
None | |||||
7. | Sole Dispositive Power
1,969,697 (See Item 4(a) below) | |||||
8. | Shared Dispositive Power
None |
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,969,697 (See Item 4(a) below) | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
5.9% (See Item 4(b) below) | |||||
12. | Type of Reporting Person (See Instructions)
CO |
(1) | This number represents the percentage obtained by: dividing (a) the total number of shares of the Issuers common stock being reported in this Statement 1,969,697) by (b) the number of shares of the Issuers common stock outstanding on May 14, 2019 (33,637,501), based on information publicly disclosed by the Issuer. |
-2-
Explanatory Note
This Schedule 13G is filed to report the Reporting Persons (as defined below) ownership of shares of common stock, $0.001 par value per share, of CytRx Corporation (the common stock). The Reporting Persons current beneficial ownership of the common stock is set forth on the cover page hereto.
Item 1. |
(a) | Name of Issuer: |
CytRx Corporation
(b) | Address of Issuers Principal Executive Offices: |
11726 San Vicente Blvd, Suite 650
Los Angeles, California 90049
Item 2. |
(a) | Name of Person Filing: |
Patrick Soon-Shiong, M.D. and ImmunityBio, Inc. (IB). Dr. Soon-Shiong, through affiliated entities (Cambridge Equities, LP, MP 13 Ventures, LLC, California Capital Equity, LLC, Nantworks, LLC, and NantBio, Inc.) indirectly owns a majority-in-interest of the voting and dispositive power of IB. Dr. Soon-Shiong is also the sole member of the board of directors of IB. Each of IB and Dr. Soon-Shiong may be referred to herein as a Reporting Person.
(b) | Address of Principal Business Office or, if none, Residence: |
9920 Jefferson Blvd
Culver City, California 90232
(c) | Citizenship: |
Dr. Soon-Shiong is a U.S. citizen. IB is a corporation organized under the laws of the State of Delaware.
(d) | Title of Class of Securities: |
Common Stock, $0.001 par value per share
(e) | CUSIP Number: |
232828608
Item 3. | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
Not applicable. |
-3-
Item 4. | Ownership. |
(a) | Amount beneficially owned: |
1,969,697 shares of common stock
(b) | Percent of class: |
5.9%
The ownership percentage above is calculated by dividing (a) the total number of shares of the Issuers common stock being reported in this Statement (1,969,697) by (b) the number of shares of the Issuers common stock outstanding on May 14, 2019 (33,637,501), based on information publicly disclosed by the Issuer.
(c) | Number of shares as to which the person has: |
(i) | Sole power to vote or to direct the vote |
1,969,697 shares (1)
(ii) | Shared power to vote or to direct the vote |
None
(iii) | Sole power to dispose or to direct the disposition of |
1,969,697 shares (1)
(iv) | Shared power to dispose or to direct the disposition of |
None
(1) | Consists of 1,969,697 shares of Common Stock held of record by IB as of June 6, 2019. |
Item 5. | Ownership of Five Percent or Less of a Class. |
Not applicable. |
Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable. |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not applicable. |
Item 8. | Identification and Classification of Members of the Group. |
Not applicable. |
-4-
Item 9. | Notice of Dissolution of Group. |
Not applicable. |
Item 10. | Certifications. |
Not applicable. |
-5-
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: June 6, 2019 | ||
PATRICK SOON-SHIONG | ||
By: | /s/ Patrick Soon-Shiong | |
Name: Patrick Soon-Shiong |
IMMUNITYBIO, INC. | ||
By: | /s/ Charles Kim | |
Name: Charles Kim | ||
Title: General Counsel |
-6-